Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compared to a placebo. To answer this hypothesis, the investigators are conducting a randomized controlled trial in which half of participants will receive TXA and half will receive placebo (saline) in a double blind fashion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Undergoing endoscopic pituitary surgery at UNC

Exclusion Criteria:

• Clival invasion

• Giant pituitary tumor (>4 cm)

• Revision pituitary surgery

• Prior sinus surgery

• Lund McKay score > 3

• Active thromboembolic disease

• Coagulopathy

• Concomitant pro-thrombotic medications

• Concomitant use of anti-coagulants or anti-platelet agents

• Subarachnoid hemorrhage

• History of severe hypersensitivity to Tranexamic Acid